Repligen looks set to ride long-term growth in medicines made from living cells, but rising costs, supply chain friction, and tougher pricing pressure could slow that momentum. A rebound in China and a wave of new product launches offer upside, yet heavy reliance on a few big customers and tighter biotech funding could make results choppier than many expect.Read more
Key Takeaways Increased focus on innovative, higher-margin products and expanded global manufacturing aims to strengthen recurring revenue and drive resilient, long-term growth. Strategic diversification across modalities and regions reduces reliance on any one market, supporting margin expansion and consistent operational performance.Read more
Key Takeaways Repligen is positioned for sustained above-industry growth, driven by portfolio breadth, automation, and strategic focus on higher-margin opportunities, exceeding consensus expectations for revenue and margins. Expansion into Asia-Pacific and rising bioprocess outsourcing are set to fuel long-term demand, recurring revenues, and reduced geographic risk for the company.Read more
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company’s products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
